Viral entry denied

New England Journal of Medicine

Volumn 351, Issue 8, 2004, Pages 743-744

  Doms, Robert W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; EBOLA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIROLOGY;

ANTIVIRAL AGENTS; HIV FUSION INHIBITORS; HUMANS; MEMBRANE FUSION; RECEPTORS, CELL SURFACE; VIRAL ENVELOPE PROTEINS;

EID: 4143094991     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMp048058     Document Type: Review

References (3)

1. Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004;101:2536-41.
2. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A 2003;100: 10598-602.
3. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004;427:313-9.